Core Viewpoint - Rosen Law Firm is encouraging investors of Baxter International Inc. to secure legal counsel before the December 15, 2025 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [1][2]. Group 1: Class Action Details - Investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 15, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Allegations Against Baxter - The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in the Novum IQ Large Volume Pump, which led to malfunctions and posed serious risks to patients [5]. - Specific issues cited include underinfusion, overinfusion, and complete non-delivery of fluids, along with inadequate remedial measures taken by Baxter in response to reported malfunctions and injuries [5]. - The lawsuit claims that Baxter's statements regarding the safety and efficacy of the Novum LVPs were materially false and misleading, resulting in investor damages when the true details became public [5].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud affecting investors between February 23, 2022, and July 30, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that Baxter's product, the Novum LVP, had systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [3]. - It is alleged that Baxter was aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - The lawsuit suggests that there was an increased risk of customers being instructed to take Novum LVPs out of service and that Baxter would halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff [4]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as a leading securities litigation firm in the United States [5].

Core Viewpoint - The Baxter Foundation is continuing its partnership with Northwestern University's School of Education and Social Policy to enhance STEM education in the Chicagoland area through a significant financial commitment [1] Group 1: Partnership Details - The partnership aims to provide science, technology, engineering, and math (STEM) programs for students and teachers [1] - The initiative is supported by a three-year grant amounting to $2.6 million from the Baxter Foundation [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, of the December 15, 2025, deadline to become a lead plaintiff in a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Baxter common stock during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must act by December 15, 2025, to serve as lead plaintiff [4][6]. - The lawsuit alleges that Baxter misled investors regarding the safety and efficacy of the Novum IQ Large Volume Pump, which suffered systemic defects leading to serious risks for patients [6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [5]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [5]. Group 3: Case Specifics - The lawsuit claims that Baxter was aware of multiple malfunctions and injuries related to the Novum LVP but failed to adequately address these issues, leading to misleading statements about the product's safety and sales prospects [6].

Core Viewpoint - Baxter International, Inc. is facing a federal securities class action lawsuit due to allegations of misleading investors regarding the safety and performance of its Novum LVP device, which has been linked to serious patient risks and malfunctions [3][4]. Summary by Sections Lawsuit Details - The lawsuit is on behalf of investors who acquired Baxter securities between February 23, 2022, and July 30, 2025, alleging that the company failed to disclose critical safety issues with the Novum LVP [3]. - Allegations include systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which posed risks of serious injury or death to patients [3]. Safety Concerns - Safety issues regarding the Novum LVP emerged on April 7, 2025, following a whistleblower report about inaccurate infusion [4]. - Baxter issued warning letters to customers about underinfusion risks, initially disclosing only one serious injury, but later acknowledging 79 reports of serious injuries and two patient deaths related to the device [4]. Financial Impact - Following the announcement of a voluntary pause in shipments and installations of the Novum LVP on July 31, 2025, Baxter's share price fell by $6.29, approximately 22.4%, from $28.05 to $21.76 [4].

Core Viewpoint - A class action securities lawsuit has been filed against Baxter International, Inc. due to alleged securities fraud related to the company's product malfunctions and inadequate responses to these issues [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between February 23, 2022, and July 30, 2025 [1]. - The complaint alleges that Baxter's Novum LVP product suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing serious risks to patients [2]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths linked to these defects, yet their remedial measures were deemed inadequate [2]. Group 2: Implications for Baxter - Due to the ongoing issues with the Novum LVP, there is a heightened risk that customers may be instructed to take these devices out of service, potentially halting all new sales [2]. - Baxter's statements regarding the safety, efficacy, and sales prospects of the Novum LVPs have been characterized as materially false and misleading [2]. Group 3: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 15, 2025, to request appointment as lead plaintiff, although participation does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities law violations at Baxter International Inc. following serious safety concerns related to its Novum IQ Large Volume Pump, which has led to significant investor losses and stock price decline [2][3][5]. Group 1: Safety Concerns and Legal Investigation - A Missouri news outlet reported serious safety issues with Baxter's Novum IQ Large Volume Pump, citing a whistleblower who claimed the pumps were unsafe for patient treatment [3]. - Baxter acknowledged potential under infusion risks in warning letters to customers, disclosing one serious injury linked to the device [4]. - The FDA classified the situation as a Class I recall, indicating a severe risk of serious injury or death, with Baxter reporting 79 serious injury cases and two patient deaths associated with the device [4]. Group 2: Stock Price Impact - Following the announcement of a voluntary and temporary pause in shipments and installations of the Novum LVP, Baxter's stock price fell by $6.24 per share, or 22.4%, closing at $21.61 per share on July 31, 2025 [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Baxter International Inc. for misrepresentations regarding the safety of its Novum IQ Large Volume Pump, which allegedly concealed systemic issues that could endanger patients [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Baxter common stock between February 23, 2022, and July 30, 2025 [1]. - The defendants are accused of misrepresenting the safety of the Novum IQ Large Volume Pump, which is used for intravenous fluid delivery, while hiding serious risks associated with the device [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by December 15, 2025, although participation as a class member does not require serving as a lead plaintiff [4]. - All legal representation in this case is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [5]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" and listed in The Legal 500 for sixteen consecutive years [5].

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Group 1: Allegations and Issues - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address the issues through customer alerts [1]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to July 30, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 15, 2025, with no cost or obligation to participate in the case [2]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased Baxter common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...